{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:04:41Z","timestamp":1792098281711,"version":"4.4.0"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,1,22]],"date-time":"2013-01-22T00:00:00Z","timestamp":1358812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,1,22]],"date-time":"2013-01-22T00:00:00Z","timestamp":1358812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1038\/nrneph.2012.289","type":"journal-article","created":{"date-parts":[[2013,1,22]],"date-time":"2013-01-22T08:52:31Z","timestamp":1358844751000},"page":"154-169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["Rituximab therapy in nephrotic syndrome: implications for patients' management"],"prefix":"10.1038","volume":"9","author":[{"given":"Aditi","family":"Sinha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Bagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,22]]},"reference":[{"key":"BFnrneph2012289_CR1","doi-asserted-by":"publisher","first-page":"770","DOI":"10.2741\/3719","volume":"16","author":"A Amoroso","year":"2011","unstructured":"Amoroso, A.  et al. Understanding rituximab function and resistance: implications for tailored therapy. Front. Biosci. 16, 770\u2013782 (2011).","journal-title":"Front. Biosci."},{"key":"BFnrneph2012289_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4161\/mabs.4.2.19286","volume":"4","author":"AA Ejaz","year":"2012","unstructured":"Ejaz, A. A., Asmar, A., Alsabbagh, M. M. & Ahsan, N. Rituximab in immunologic glomerular diseases. mAbs 4, 198\u2013207 (2012).","journal-title":"mAbs"},{"key":"BFnrneph2012289_CR3","unstructured":"US Food and Drug Administration. News and events [online], (2012)."},{"key":"BFnrneph2012289_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1442-200X.2011.03432.x","volume":"53","author":"K Iijima","year":"2011","unstructured":"Iijima, K. Rituximab for childhood refractory nephrotic syndrome. Pediatr. Int. 53, 617\u2013621 (2011).","journal-title":"Pediatr. Int."},{"key":"BFnrneph2012289_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10157-011-0465-6","volume":"15","author":"T Takei","year":"2011","unstructured":"Takei, T. & Nitta, K. Rituximab and minimal change nephrotic syndrome: a therapeutic option. Clin. Exp. Nephrol. 15, 641\u2013647 (2011).","journal-title":"Clin. Exp. Nephrol."},{"key":"BFnrneph2012289_CR6","doi-asserted-by":"publisher","unstructured":"Araya, C. E. & Dharnidharka, V. R. The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review. J. Transplant. http:\/\/dx.doi.org\/10.1155\/2011\/374213.","DOI":"10.1155\/2011\/374213"},{"key":"BFnrneph2012289_CR7","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1681\/ASN.2012060602","volume":"23","author":"GB Appel","year":"2012","unstructured":"Appel, G. B. Rituximab in membranous nephropathy: is it a first-line treatment? J. Am. Soc. Nephrol. 23, 1280\u20131282 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR8","doi-asserted-by":"crossref","unstructured":"Kidney Disease Improving Global Outcomes (KDIGO). General principles in the management of glomerular disease. Kidney Int. Suppl. 2, 156\u2013162 (2012).","DOI":"10.1038\/kisup.2012.15"},{"key":"BFnrneph2012289_CR9","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/ki.2012.238","volume":"82","author":"A Gulati","year":"2012","unstructured":"Gulati, A.  et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int. 82, 1130\u20131135 (2012).","journal-title":"Kidney Int."},{"key":"BFnrneph2012289_CR10","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","volume":"66","author":"S Troyanov","year":"2004","unstructured":"Troyanov, S.  et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 66, 1199\u20131205 (2004).","journal-title":"Kidney Int."},{"key":"BFnrneph2012289_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000082102","volume":"8","author":"MS Cragg","year":"2005","unstructured":"Cragg, M. S., Walshe, C. A., Ivanov, A. O. & Glennie, M. J. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8, 140\u2013174 (2005).","journal-title":"Curr. Dir. Autoimmun."},{"key":"BFnrneph2012289_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1006\/bcmd.2000.0287","volume":"26","author":"JK Hofmeister","year":"2000","unstructured":"Hofmeister, J. K., Cooney, D. & Coggeshall, K. M. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx and caspase 3-dependent apoptosis. Blood Cells Mol. Dis. 26, 133\u2013143 (2000).","journal-title":"Blood Cells Mol. Dis."},{"key":"BFnrneph2012289_CR13","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","volume":"104","author":"G Cartron","year":"2004","unstructured":"Cartron, G., Watier, H., Golay, J. & Solal-Celigny, P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104, 2635\u20132642 (2004).","journal-title":"Blood"},{"key":"BFnrneph2012289_CR14","first-page":"534","volume":"63","author":"I Semac","year":"2003","unstructured":"Semac, I.  et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts\/microdomains of B lymphoma cells. Cancer Res. 63, 534\u2013540 (2003).","journal-title":"Cancer Res."},{"key":"BFnrneph2012289_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/ki.1991.232","volume":"40","author":"A Koyama","year":"1991","unstructured":"Koyama, A., Fujisaki, M., Kobayashi, M., Igarashi, M. & Narita, M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int. 40, 453\u2013460 (1991).","journal-title":"Kidney Int."},{"key":"BFnrneph2012289_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.clim.2006.08.016","volume":"122","author":"T Vallerskog","year":"2007","unstructured":"Vallerskog, T.  et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with, S.L.E. Clin. Immunol. 122, 62\u201374 (2007).","journal-title":"Clin. Immunol."},{"key":"BFnrneph2012289_CR17","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","volume":"112","author":"R Stasi","year":"2008","unstructured":"Stasi, R.  et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112, 1147\u20131150 (2008).","journal-title":"Blood"},{"key":"BFnrneph2012289_CR18","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1186\/ar1954","volume":"8","author":"M Vigna-Perez","year":"2006","unstructured":"Vigna-Perez, M.  et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. 8, R83 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrneph2012289_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clim.2006.12.006","volume":"123","author":"PP Sfikakis","year":"2007","unstructured":"Sfikakis, P. P.  et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immunol. 123, 66\u201373 (2007).","journal-title":"Clin. Immunol."},{"key":"BFnrneph2012289_CR20","doi-asserted-by":"publisher","first-page":"5334","DOI":"10.1182\/blood-2007-11-122713","volume":"111","author":"D Saadoun","year":"2008","unstructured":"Saadoun, D.  et al. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 111, 5334\u20135341 (2008).","journal-title":"Blood"},{"key":"BFnrneph2012289_CR21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/art.20858","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis, P. P.  et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand. Arthritis Rheum. 52, 501\u2013513 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012289_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/rheumatology\/keh443","volume":"44","author":"M Tokunaga","year":"2005","unstructured":"Tokunaga, M.  et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 44, 176\u2013182 (2005).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrneph2012289_CR23","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1172\/JCI32405","volume":"117","author":"CY Hu","year":"2007","unstructured":"Hu, C. Y.  et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117, 3857\u20133867 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2012289_CR24","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00467-009-1214-x","volume":"24","author":"C Araya","year":"2009","unstructured":"Araya, C.  et al. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatr. Nephrol. 24, 1691\u20131698 (2009).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1681\/ASN.2007111244","volume":"20","author":"L Le Berre","year":"2009","unstructured":"Le Berre, L.  et al. Induction of T regulatory cells attenuates idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 20, 57\u201367 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR26","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00467-009-1194-x","volume":"24","author":"XS Shao","year":"2009","unstructured":"Shao, X. S.  et al. The prevalence of TH17 cells and FOXP3 regulate T cells (Treg) in children with primary nephrotic syndrome. Pediatr. Nephrol. 24, 1683\u20131690 (2009).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR27","first-page":"783","volume":"26","author":"L Wang","year":"2010","unstructured":"Wang, L., Li, Q., Wang, L. J. & Li, X. Level of TH17 cell and CD4+; CD25+; Foxp3+; regulatory T cells in peripheral blood mononuclear cells of primary nephrotic syndrome in children [Chinese]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 26, 783\u2013786 (2010).","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"BFnrneph2012289_CR28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2249.2010.04160.x","volume":"161","author":"R Bertelli","year":"2010","unstructured":"Bertelli, R.  et al. Failure of regulation results in an amplified oxidation burst by neutrophils in children with primary nephrotic syndrome. Clin. Exp. Immunol. 161, 151\u2013158 (2010).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrneph2012289_CR29","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00467-010-1676-x","volume":"26","author":"M Shimada","year":"2011","unstructured":"Shimada, M.  et al. Minimal change disease: a \u201ctwo-hit\u201d podocyte immune disorder? Pediatr. Nephrol. 26, 645\u2013649 (2011).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR30","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.2215\/CJN.05080610","volume":"5","author":"FC Fervenza","year":"2010","unstructured":"Fervenza, F. C.  et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin. J. Am. Soc. Nephrol. 5, 2188\u20132198 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR31","first-page":"403","volume":"21","author":"WS Yeo","year":"2010","unstructured":"Yeo, W. S.  et al. Effect of rituximab on T-cell subsets in nephrotic children with focal segmental glomerulosclerosis (FSGS) [abstract F-PO1277]. J. Am. Soc. Nephrol. 21, 403 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR32","first-page":"724","volume":"23","author":"CY Lin","year":"2012","unstructured":"Lin, C. Y. Immune modulatory mechanism of rituximab in steroid refractory heavy proteinuria [abstract SA-PO377]. J. Am. Soc. Nephrol. 23, 724 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR33","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2005-04-1769","volume":"107","author":"F Perosa","year":"2006","unstructured":"Perosa, F., Favoino, E., Caragnano, M. A. & Dammacco, F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 107, 1070\u20131077 (2006).","journal-title":"Blood"},{"key":"BFnrneph2012289_CR34","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2004-01-0277","volume":"104","author":"C Bezombes","year":"2004","unstructured":"Bezombes, C.  et al. Rituximab antiproliferative effect in B lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 104, 1166\u20131173 (2004).","journal-title":"Blood"},{"key":"BFnrneph2012289_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni, A.  et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl. Med. 3, 85\u201395 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnrneph2012289_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.yexmp.2012.06.001","volume":"94","author":"R Tan","year":"2013","unstructured":"Tan, R.  et al. Nef interaction with actin compromises human podocyte actin cytoskeletal integrity. Exp. Mol. Pathol. 94, 51\u201357 (2013).","journal-title":"Exp. Mol. Pathol."},{"key":"BFnrneph2012289_CR37","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nm.2411","volume":"17","author":"C Wei","year":"2011","unstructured":"Wei, C.  et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952\u2013960 (2011).","journal-title":"Nat. Med."},{"key":"BFnrneph2012289_CR38","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1681\/ASN.2012010050","volume":"23","author":"CY Chan","year":"2012","unstructured":"Chan, C. Y., Yeo, W. S., Wei, C., Biswas, S. K. & Yap, H. K. High suPAR levels in FSGS patients is associated with decreased TREG cells [abstract FR-PO483]. J. Am. Soc. Nephrol. 23, 484 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR39","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online], (2012)."},{"key":"BFnrneph2012289_CR40","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.clim.2011.02.018","volume":"139","author":"LL Liu","year":"2011","unstructured":"Liu, L. L.  et al. TH17\/TREG imbalance in adult patients with minimal change nephrotic syndrome. Clin. Immunol. 139, 314\u2013320 (2011).","journal-title":"Clin. Immunol."},{"key":"BFnrneph2012289_CR41","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/0091270005277075","volume":"45","author":"CM Ng","year":"2005","unstructured":"Ng, C. M., Bruno, R., Combs, D. & Davies, B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J. Clin. Pharmacol. 45, 792\u2013801 (2005).","journal-title":"J. Clin. Pharmacol."},{"key":"BFnrneph2012289_CR42","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1177\/0091270007305297","volume":"47","author":"F Breedveld","year":"2007","unstructured":"Breedveld, F.  et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J. Clin. Pharmacol. 47, 1119\u20131128 (2007).","journal-title":"J. Clin. Pharmacol."},{"key":"BFnrneph2012289_CR43","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1023\/A:1008416911099","volume":"9","author":"NL Berinstein","year":"1998","unstructured":"Berinstein, N. L.  et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 9, 995\u20131001 (1998).","journal-title":"Ann. Oncol."},{"key":"BFnrneph2012289_CR44","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei, K.  et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr. Nephrol. 24, 1321\u20131328 (2009).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sj.ki.5002628","volume":"73","author":"FC Fervenza","year":"2008","unstructured":"Fervenza, F. C.  et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 73, 117\u2013125 (2008).","journal-title":"Kidney Int."},{"key":"BFnrneph2012289_CR46","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/01.ftd.0000184162.60197.c1","volume":"27","author":"MB Regazzi","year":"2005","unstructured":"Regazzi, M. B.  et al. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogenous clinical settings. Ther. Drug Monit. 27, 785\u2013792 (2005).","journal-title":"Ther. Drug Monit."},{"key":"BFnrneph2012289_CR47","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00467-009-1377-5","volume":"25","author":"S Fujinaga","year":"2010","unstructured":"Fujinaga, S.  et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr. Nephrol. 25, 539\u2013544 (2010).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR48","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","volume":"23","author":"V Guigonis","year":"2008","unstructured":"Guigonis, V.  et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr. Nephrol. 23, 1269\u20131279 (2008).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR49","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00467-010-1465-6","volume":"25","author":"AL Sellier-Leclerc","year":"2010","unstructured":"Sellier-Leclerc, A. L.  et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 25, 1109\u20131115 (2010).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR50","doi-asserted-by":"publisher","unstructured":"Ito, S.  et al. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr. Nephrol. http:\/\/dx.doi.org\/10.1007\/s00467-012-2319-1.","DOI":"10.1007\/s00467-012-2319-1"},{"key":"BFnrneph2012289_CR51","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","volume":"27","author":"AL Sellier-Leclerc","year":"2012","unstructured":"Sellier-Leclerc, A. L.  et al. Rituximab in steroid dependent idiopathic nephrotic syndrome in childhood: follow-up after CD19 recovery. Nephrol. Dial. Transplant. 27, 1083\u20131089 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012289_CR52","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.2215\/CJN.03470410","volume":"5","author":"A Gulati","year":"2010","unstructured":"Gulati, A.  et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin. J. Am. Soc. Nephrol. 5, 2207\u20132212 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR53","doi-asserted-by":"publisher","first-page":"151","DOI":"10.5414\/CN107092","volume":"76","author":"E Hoxha","year":"2011","unstructured":"Hoxha, E., Stahl, R. A. & Harendza, S. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin. Nephrol. 76, 151\u2013158 (2011).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph2012289_CR54","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","volume":"25","author":"A Prytula","year":"2010","unstructured":"Prytula, A.  et al. Rituximab in refractory nephrotic syndrome. Pediatr. Nephrol. 25, 461\u2013468 (2010).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR55","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","volume":"27","author":"MJ Kemper","year":"2012","unstructured":"Kemper, M. J.  et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol. Dial. Transplant. 27, 1910\u20131915 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012289_CR56","first-page":"13","volume":"122","author":"A Bagga","year":"2005","unstructured":"Bagga, A. & Mantan, M. Nephrotic syndrome in children. Indian J. Med. Res. 122, 13\u201328 (2005).","journal-title":"Indian J. Med. Res."},{"key":"BFnrneph2012289_CR57","doi-asserted-by":"crossref","unstructured":"Kidney Disease Improving Global Outcomes (KDIGO). Steroid-sensitive nephrotic syndrome in children. Kidney Int. Suppl. 2, 163\u2013171 (2012).","DOI":"10.1038\/kisup.2012.16"},{"key":"BFnrneph2012289_CR58","doi-asserted-by":"publisher","unstructured":"Hodson, E. M., Willis, N. S. & Craig, J. C. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD002290. http:\/\/dx.doi.org\/10.1002\/14651858.CD002290.pub3.","DOI":"10.1002\/14651858.CD002290.pub3"},{"key":"BFnrneph2012289_CR59","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/ki.2008.24","volume":"73","author":"K Ishikura","year":"2008","unstructured":"Ishikura, K.  et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 73, 1167\u20131173 (2008).","journal-title":"Kidney Int."},{"key":"BFnrneph2012289_CR60","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","volume":"19","author":"K Benz","year":"2004","unstructured":"Benz, K., D\u00f6tsch, J., Rascher, W. & Stachel, D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr. Nephrol. 19, 794\u2013797 (2004).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR61","doi-asserted-by":"publisher","first-page":"c98","DOI":"10.1159\/000319656","volume":"117","author":"H Sugiura","year":"2011","unstructured":"Sugiura, H.  et al. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin. Pract. 117, c98\u2013c105 (2011).","journal-title":"Nephron Clin. Pract."},{"key":"BFnrneph2012289_CR62","doi-asserted-by":"publisher","first-page":"c79","DOI":"10.1159\/000335142","volume":"120","author":"T Kisner","year":"2012","unstructured":"Kisner, T., Burst, V., Teschner, S., Benzing, T. & Kurschat, C. E. Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature. Nephron Clin. Pract. 120, c79\u2013c85 (2012).","journal-title":"Nephron Clin. Pract."},{"key":"BFnrneph2012289_CR63","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2169\/internalmedicine.51.6854","volume":"51","author":"A Ochi","year":"2012","unstructured":"Ochi, A.  et al. Rituximab treatment for adult patients with focal segmental glomerulosclerosis. Intern. Med. 51, 759\u2013762 (2012).","journal-title":"Intern. Med."},{"key":"BFnrneph2012289_CR64","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00467-012-2232-7","volume":"27","author":"A Sinha","year":"2012","unstructured":"Sinha, A., Bhatia, D., Gulati, A., Hari, P. & Bagga, A. Efficacy and safety of rituximab in difficult steroid resistant & dependent nephrotic syndrome [abstract OP64]. Pediatr. Nephrol. 27, 1605\u20131829 (2012).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR65","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani, P.  et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin. J. Am. Soc. Nephrol. 6, 1308\u20131315 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR66","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1681\/ASN.2011080775","volume":"23","author":"A Magnasco","year":"2012","unstructured":"Magnasco, A.  et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 23, 1117\u20131124 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR67","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00467-011-1886-x","volume":"26","author":"S Ito","year":"2011","unstructured":"Ito, S.  et al. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 26, 1823\u20131828 (2011).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR68","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00467-011-1997-4","volume":"27","author":"A Sinha","year":"2012","unstructured":"Sinha, A., Bagga, A., Gulati, A. & Hari, P. Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 27, 235\u2013241 (2012).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR69","first-page":"484","volume":"23","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti, P.  et al. Rituximab in steroid-dependent or multirelapsing nephrotic syndrome of adults and children: results from the NEMO trial [abstract SA-PO375]. J. Am. Soc. Nephrol. 23, 484 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR70","unstructured":"Japan Medical Association for Clinical Trials. Double-Blind Study of IDEC-C2B8 in patients with childhood-onset refractory nephrotic syndrome. JMACCT Clinical Trials Registry [online], (2012)."},{"key":"BFnrneph2012289_CR71","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online], (2012)."},{"key":"BFnrneph2012289_CR72","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1056\/NEJMc063706","volume":"356","author":"A Bagga","year":"2007","unstructured":"Bagga, A., Sinha, A. & Moudgil, A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N. Engl. J. Med. 356, 2751\u20132752 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012289_CR73","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.2169\/internalmedicine.48.2435","volume":"48","author":"N Kurosu","year":"2009","unstructured":"Kurosu, N.  et al. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. Intern. Med. 48, 1901\u20131904 (2009).","journal-title":"Intern. Med."},{"key":"BFnrneph2012289_CR74","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s11255-008-9393-0","volume":"40","author":"M Suri","year":"2008","unstructured":"Suri, M., Tran, K., Sharma, A. P., Filler, G. & Grimmer, J. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab. Int. Urol. Nephrol. 40, 807\u2013810 (2008).","journal-title":"Int. Urol. Nephrol."},{"key":"BFnrneph2012289_CR75","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00467-007-0640-x","volume":"23","author":"M Nakayama","year":"2008","unstructured":"Nakayama, M.  et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr. Nephrol. 23, 481\u2013485 (2008).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR76","first-page":"408","volume":"66","author":"HP Peters","year":"2008","unstructured":"Peters, H. P., van de Kar, N. C. & Wetzels, J. F. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature. Neth. J. Med. 66, 408\u2013415 (2008).","journal-title":"Neth. J. Med."},{"key":"BFnrneph2012289_CR77","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2215\/CJN.00570109","volume":"4","author":"G Fernandez-Fresnedo","year":"2009","unstructured":"Fernandez-Fresnedo, G.  et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 4, 1317\u20131323 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR78","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00467-011-1778-0","volume":"26","author":"JA Kari","year":"2011","unstructured":"Kari, J. A.  et al. Rituximab for refractory cases of childhood nephrotic syndrome. Pediatr. Nephrol. 26, 733\u2013737 (2011).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR79","doi-asserted-by":"publisher","unstructured":"Kong, W. Y., Swaminathan, R. & Irish, A. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int. Urol. Nephrol. http:\/\/dx.doi.org\/10.1007\/s11255-012-0206-0.","DOI":"10.1007\/s11255-012-0206-0"},{"key":"BFnrneph2012289_CR80","first-page":"283","volume":"3","author":"W Couser","year":"2005","unstructured":"Couser, W. Recurrent glomerulonephritis in the renal allograft: an update of selected areas. Exp. Clin. Transplant. 3, 283\u2013288 (2005).","journal-title":"Exp. Clin. Transplant."},{"key":"BFnrneph2012289_CR81","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.2215\/CJN.06720810","volume":"5","author":"C Ponticelli","year":"2010","unstructured":"Ponticelli, C. & Glassock, R. J. Posttransplant recurrence of primary glomerulonephritis. Clin. J. Am. Soc. Nephrol. 5, 2363\u20132372 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR82","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1399-3046.2009.01261.x","volume":"14","author":"M Vinai","year":"2010","unstructured":"Vinai, M., Waber, P. & Seikaly, M. G. Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review. Pediatr. Transplant. 14, 314\u2013325 (2010).","journal-title":"Pediatr. Transplant."},{"key":"BFnrneph2012289_CR83","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1523-1755.2004.00776.x","volume":"66","author":"S Weber","year":"2004","unstructured":"Weber, S.  et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int. 66, 571\u2013579 (2004).","journal-title":"Kidney Int."},{"key":"BFnrneph2012289_CR84","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1046\/j.1523-1755.2001.00494.x","volume":"59","author":"MA Baum","year":"2001","unstructured":"Baum, M. A.  et al. Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int. 59, 328\u2013333 (2001).","journal-title":"Kidney Int."},{"key":"BFnrneph2012289_CR85","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1034\/j.1600-6143.2003.30111.x","volume":"3","author":"DM Cibrik","year":"2003","unstructured":"Cibrik, D. M., Kaplan, B., Campbell, D. A. & Meier-Kriesche, H. U. Renal allograft survival in transplant recipients with focal segmental glomerulosclerosis. Am. J. Transplant. 3, 64\u201367 (2003).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph2012289_CR86","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00007890-199909150-00007","volume":"68","author":"S Hariharan","year":"1999","unstructured":"Hariharan, S.  et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 68, 635\u2013641 (1999).","journal-title":"Transplantation"},{"key":"BFnrneph2012289_CR87","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/ndt\/gfk005","volume":"21","author":"A Pardon","year":"2006","unstructured":"Pardon, A.  et al. Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrol. Dial. Transplant. 21, 1053\u20131059 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"Suppl. 6","key":"BFnrneph2012289_CR88","first-page":"68","volume":"18","author":"CG Newstead","year":"2003","unstructured":"Newstead, C. G. Recurrent disease in renal transplants. Nephrol. Dial. Transplant. 18 (Suppl. 6), 68\u201374 (2003).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012289_CR89","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/ndt\/gfp538","volume":"25","author":"C Ponticelli","year":"2010","unstructured":"Ponticelli, C. Recurrence of focal segmental glomerular sclerosis after renal transplantation. Nephrol. Dial. Transplant. 25, 25\u201331 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012289_CR90","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1007\/s00467-005-2013-7","volume":"20","author":"K Nozu","year":"2005","unstructured":"Nozu, K.  et al. Rituximab treatment for posttransplant lymphoproliferative disorder induces complete remission of recurrent nephrotic syndrome. Pediatr. Nephrol. 20, 1660\u20131663 (2005).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR91","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1399-0012.2010.01279.x","volume":"24","author":"K Sakai","year":"2010","unstructured":"Sakai, K.  et al. Protocol biopsies for focal segmental glomerulosclerosis treated with plasma exchange and rituximab in a renal transplant patient. Clin. Transplant. 24, 60\u201365 (2010).","journal-title":"Clin. Transplant."},{"key":"BFnrneph2012289_CR92","doi-asserted-by":"publisher","unstructured":"Kumar, J.  et al. Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis. Pediatr. Nephrol. http:\/\/dx.doi.org\/10.1007\/s00467-012-2314-6.","DOI":"10.1007\/s00467-012-2314-6"},{"key":"BFnrneph2012289_CR93","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1525-1594.2010.01068.x","volume":"35","author":"G Tsagalis","year":"2011","unstructured":"Tsagalis, G., Psimenou, E., Nakopoulou, L. & Laggouranis, A. Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation. Artif. Organs 35, 420\u2013425 (2011).","journal-title":"Artif. Organs"},{"key":"BFnrneph2012289_CR94","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1016\/j.transproceed.2011.10.051","volume":"43","author":"ZA Stewart","year":"2011","unstructured":"Stewart, Z. A., Shetty, R., Nair, R., Reed, A. I. & Brophy, P. D. Case report: successful treatment of recurrent focal segmental glomerulosclerosis with a novel rituximab regimen. Transplant. Proc. 43, 3994\u20133996 (2011).","journal-title":"Transplant. Proc."},{"key":"BFnrneph2012289_CR95","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1432-2277.2007.00477.x","volume":"20","author":"J Gossmann","year":"2007","unstructured":"Gossmann, J.  et al. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl. Int. 20, 558\u2013562 (2007).","journal-title":"Transpl. Int."},{"key":"BFnrneph2012289_CR96","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1111\/j.1399-3046.2010.01440.x","volume":"15","author":"R Grenda","year":"2011","unstructured":"Grenda, R., Jarmuz\u02d9ek, W., Pia\u02dbto sa, B. & Rubik, J. Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation-case report. Pediatr. Transplant. 15, e121\u2013e125 (2011).","journal-title":"Pediatr. Transplant."},{"key":"BFnrneph2012289_CR97","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1111\/j.1432-2277.2012.01462.x","volume":"25","author":"V Audard","year":"2012","unstructured":"Audard, V.  et al. Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation. Transpl. Int. 25, e62\u2013e66 (2012).","journal-title":"Transpl. Int."},{"key":"BFnrneph2012289_CR98","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1111\/j.1399-3046.2011.01610.x","volume":"16","author":"H Chikamoto","year":"2012","unstructured":"Chikamoto, H.  et al. Pretransplantation combined therapy with plasmapheresis and rituximab in a second living-related kidney transplant pediatric recipient with a very high risk for focal segmental glomerulosclerosis recurrence. Pediatr. Transplant. 16, e286\u2013e290 (2012).","journal-title":"Pediatr. Transplant."},{"key":"BFnrneph2012289_CR99","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1111\/j.1600-6143.2005.01112.x","volume":"5","author":"RY Gohh","year":"2005","unstructured":"Gohh, R. Y.  et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am. J. Transplant. 5, 2907\u20132912 (2005).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph2012289_CR100","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/j.1538-7836.2010.03818.x","volume":"8","author":"V McDonald","year":"2010","unstructured":"McDonald, V., Manns, K., Mackie, I. J., Machin, S. J. & Scully, M. A. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 8, 1201\u20131208 (2010).","journal-title":"J. Thromb. Haemost."},{"key":"BFnrneph2012289_CR101","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","volume":"3","author":"RJ Glassock","year":"2003","unstructured":"Glassock, R. J. Diagnosis and natural course of membranous nephropathy. Semin. Nephrol. 3, 324\u2013332 (2003).","journal-title":"Semin. Nephrol."},{"key":"BFnrneph2012289_CR102","doi-asserted-by":"crossref","unstructured":"[No authors listed]. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 13, 159\u2013165 (1978).","DOI":"10.1038\/ki.1978.23"},{"key":"BFnrneph2012289_CR103","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ki.2010.34","volume":"77","author":"LH Beck","year":"2010","unstructured":"Beck, L. H. & Salant, D. J. Membranous nephropathy: recent travels and new roads ahead. Kidney Int. 77, 765\u2013770 (2010).","journal-title":"Kidney Int."},{"key":"BFnrneph2012289_CR104","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1053\/j.ajkd.2008.06.006","volume":"52","author":"CH Zeng","year":"2008","unstructured":"Zeng, C. H.  et al. Etiology and clinical characteristics of membranous nephropathy in Chinese patients. Am. J. Kidney Dis. 52, 691\u2013698 (2008).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012289_CR105","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1681\/ASN.2009080861","volume":"21","author":"N Polanco","year":"2010","unstructured":"Polanco, N.  et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 21, 697\u2013704 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR106","unstructured":"Schieppati, A.  et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD004293. http:\/\/dx.doi.org\/search\/site\/CD004293."},{"key":"BFnrneph2012289_CR107","doi-asserted-by":"crossref","unstructured":"Kidney Disease Improving Global Outcomes (KDIGO). Idiopathic membranous nephropathy. Kidney Int. Suppl. 2, 186\u2013197 (2012).","DOI":"10.1038\/kisup.2012.20"},{"key":"BFnrneph2012289_CR108","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2215\/CJN.11001210","volume":"6","author":"DC Cattran","year":"2011","unstructured":"Cattran, D. C., Reich, H. N., Kim, S. J. & Troyanov, S. Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy. Clin. J. Am. Soc. Nephrol. 6, 1591\u20131598 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR109","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","volume":"360","author":"G Remuzzi","year":"2002","unstructured":"Remuzzi, G.  et al. Rituximab for idiopathic membranous nephropathy. Lancet 360, 923\u2013924 (2002).","journal-title":"Lancet"},{"key":"BFnrneph2012289_CR110","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck","year":"2009","unstructured":"Beck, L. H.  et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11\u201321 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012289_CR111","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1681\/ASN.2010111125","volume":"22","author":"LH Beck Jr","year":"2011","unstructured":"Beck, L. H. Jr  et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1543\u20131550 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR112","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.2215\/CJN.07210810","volume":"6","author":"JM Hofstra","year":"2011","unstructured":"Hofstra, J. M., Beck, L. H. Jr, Beck, D. M., Wetzels, J. F. & Salant, D. J. Antiphospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 6, 1286\u20131291 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR113","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMc1003066","volume":"363","author":"RAK Stahl","year":"2010","unstructured":"Stahl, R. A. K., Hoxha, E. & Fechner, K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N. Engl. J. Med. 363, 496\u2013498 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012289_CR114","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000333068","volume":"1","author":"PA Michel","year":"2011","unstructured":"Michel, P. A.  et al. Rituximab treatment for membranous nephropathy: a French clinical and serological retrospective study of 28 patients. Nephron Extra 1, 251\u2013261 (2011).","journal-title":"Nephron Extra"},{"key":"BFnrneph2012289_CR115","doi-asserted-by":"publisher","unstructured":"Murtas, C.  et al. Co-existence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin. J. Am. Soc. Nephrol. http:\/\/dx.doi.org\/10.2215\/CJN.02170312.","DOI":"10.2215\/CJN.02170312"},{"key":"BFnrneph2012289_CR116","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/ndt\/gfr247","volume":"26","author":"E Hoxha","year":"2011","unstructured":"Hoxha, E.  et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol. Dial. Transplant. 26, 2526\u20132532 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012289_CR117","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2215\/CJN.05231008","volume":"4","author":"AS Bomback","year":"2009","unstructured":"Bomback, A. S.  et al. Rituximab therapy for membranous nephropathy: a systematic review. Clin. J. Am. Soc. Nephrol. 4, 734\u2013744 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR118","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2215\/CJN.06041108","volume":"4","author":"A Segarra","year":"2009","unstructured":"Segarra, A.  et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin. J. Am. Soc. Nephrol. 4, 1083\u20131088 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR119","doi-asserted-by":"publisher","first-page":"790","DOI":"10.2215\/CJN.04120609","volume":"5","author":"B Sprangers","year":"2010","unstructured":"Sprangers, B.  et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin. J. Am. Soc. Nephrol. 5, 790\u2013797 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR120","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1159\/000327611","volume":"33","author":"P Cravedi","year":"2011","unstructured":"Cravedi, P.  et al. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am. J. Nephrol. 33, 461\u2013468 (2011).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph2012289_CR121","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","volume":"23","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti, P.  et al. Rituximab in idiopathic membranous glomerulonephritis, J. Am. Soc. Nephrol. 23, 1416\u20131425 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR122","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1600-6143.2011.03903.x","volume":"12","author":"EF Rodriguez","year":"2012","unstructured":"Rodriguez, E. F.  et al. The pathology and clinical features of early recurrent membranous glomerulonephritis. Am. J. Transplant. 12, 1029\u20131038 (2012).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph2012289_CR123","doi-asserted-by":"publisher","first-page":"738","DOI":"10.2215\/CJN.01080905","volume":"1","author":"P Ruggenenti","year":"2006","unstructured":"Ruggenenti, P.  et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin. J. Am. Soc. Nephrol. 1, 738\u2013748 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR124","doi-asserted-by":"publisher","unstructured":"Irazabal, M. V.  et al. Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Nephrol. Dial. Transplant. http:\/\/dx.doi.org\/10.1093\/ndt\/gfs379.","DOI":"10.1093\/ndt\/gfs379"},{"key":"BFnrneph2012289_CR125","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online], (2012)."},{"key":"BFnrneph2012289_CR126","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online], (2012)."},{"key":"BFnrneph2012289_CR127","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1542\/peds.2009-3395","volume":"126","author":"DS Ardelean","year":"2010","unstructured":"Ardelean, D. S.  et al. Severe ulcerative colitis after rituximab therapy. Pediatrics 126, e243\u2013e246 (2010).","journal-title":"Pediatrics"},{"key":"BFnrneph2012289_CR128","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/TP.0b013e3181aed9d7","volume":"88","author":"DL Strologo","year":"2009","unstructured":"Strologo, D. L.  et al. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation 88, 417\u2013420 (2009).","journal-title":"Transplantation"},{"key":"BFnrneph2012289_CR129","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1200\/JOP.200001","volume":"6","author":"J Atmar","year":"2010","unstructured":"Atmar, J. Review of the safety and feasibility of rapid infusion of rituximab. J. Oncol. Practice 6, 91\u201393 (2010).","journal-title":"J. Oncol. Practice"},{"key":"BFnrneph2012289_CR130","doi-asserted-by":"publisher","first-page":"250","DOI":"10.5414\/CNP67250","volume":"67","author":"N Kamar","year":"2007","unstructured":"Kamar, N.  et al. Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin. Nephrol. 67, 250\u2013254 (2007).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph2012289_CR131","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1399-3046.2008.00967.x","volume":"13","author":"US Bayrakci","year":"2009","unstructured":"Bayrakci, U. S., Baskin, E., Sakalli, H., Karakayali, H. & Haberal, M. Rituximab for post-transplant recurrences of FSGS. Pediatr. Transplant. 13, 240\u2013243 (2009).","journal-title":"Pediatr. Transplant."},{"key":"BFnrneph2012289_CR132","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1016\/S0021-9258(18)53411-6","volume":"268","author":"C Thevenin","year":"1993","unstructured":"Thevenin, C., Lucas, B. P., Kozlow, E. J. & Kehrl, J. H. Cell type- and stage-specific expression of the CD20\/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter. J. Biol. Chem. 268, 5949\u20135956 (1993).","journal-title":"J. Biol. Chem."},{"key":"BFnrneph2012289_CR133","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/10428190701742506","volume":"49","author":"SH Lim","year":"2008","unstructured":"Lim, S. H.  et al. B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leuk. Lymphoma 49, 152\u2013153 (2008).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrneph2012289_CR134","first-page":"676","volume":"19","author":"QS Wang","year":"2011","unstructured":"Wang, Q. S.  et al. Change of serum immunoglobulin level in patients with diffuse large B cell lymphoma after rituximab combined with chemotherapy [Chinese]. Zhongguo Shi Yan Xue Ye Za Zhi 19, 676\u2013679 (2011).","journal-title":"Zhongguo Shi Yan Xue Ye Za Zhi"},{"key":"BFnrneph2012289_CR135","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1365-2141.2009.07715.x","volume":"146","author":"N Cooper","year":"2009","unstructured":"Cooper, N., Davies, E. G. & Thrasher, A. J. Repeated course of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br. J. Haematol. 146, 120\u2013122 (2009).","journal-title":"Br. J. Haematol."},{"key":"BFnrneph2012289_CR136","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00296-010-1526-y","volume":"31","author":"YH Lee","year":"2011","unstructured":"Lee, Y. H., Bae, S. C. & Song, G. G. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol. Int. 31, 1493\u20131499 (2011).","journal-title":"Rheumatol. Int."},{"key":"BFnrneph2012289_CR137","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1741-7015-9-36","volume":"9","author":"S Lanini","year":"2011","unstructured":"Lanini, S.  et al. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med. 9, 36 (2011).","journal-title":"BMC Med."},{"key":"BFnrneph2012289_CR138","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/jnci\/djr418","volume":"103","author":"L Vidal","year":"2011","unstructured":"Vidal, L.  et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J. Natl Cancer Inst. 103, 1799\u20131806 (2011).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrneph2012289_CR139","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/10428190902730219","volume":"50","author":"S Aksoy","year":"2009","unstructured":"Aksoy, S., Dizdar, O., Hayran, M. & Harputluog\u02d8lu, H. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk. Lymphoma 50, 357\u2013365 (2009).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrneph2012289_CR140","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00467-012-2286-6","volume":"1","author":"M Sato","year":"2013","unstructured":"Sato, M.  et al. Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr. Nephrol. 1, 145\u2013149 (2013).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR141","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1093\/rheumatology\/ken234","volume":"47","author":"LL Teichmann","year":"2008","unstructured":"Teichmann, L. L.  et al. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford) 47, 1256\u20131257 (2008).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrneph2012289_CR142","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1136\/adc.2007.126276","volume":"93","author":"A Podolskaya","year":"2008","unstructured":"Podolskaya, A., Stadermann, M., Pilkington, C., Marks, S. D. & Tullus, K. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch. Dis. Child. 93, 401\u2013406 (2008).","journal-title":"Arch. Dis. Child."},{"key":"BFnrneph2012289_CR143","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.2215\/CJN.03710411","volume":"6","author":"J Kahwaji","year":"2011","unstructured":"Kahwaji, J.  et al. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin. J. Am. Soc. Nephrol. 6, 2894\u20132900 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012289_CR144","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1600-6143.2009.02785.x","volume":"10","author":"N Kamar","year":"2010","unstructured":"Kamar, N.  et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am. J. Transplant. 10, 89\u201398 (2010).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph2012289_CR145","doi-asserted-by":"publisher","unstructured":"Tsutsumi, Y.  et al. Rituximab administration and reactivation of, H. B. V. Hepat. Res. Treat. http:\/\/dx.doi.org\/10.1155\/2010\/182067.","DOI":"10.1155\/2010\/182067"},{"key":"BFnrneph2012289_CR146","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.3748\/wjg.v17.i34.3881","volume":"17","author":"CM Mastroianni","year":"2011","unstructured":"Mastroianni, C. M.  et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J. Gastroenterol. 17, 3881\u20133887 (2011).","journal-title":"World J. Gastroenterol."},{"issue":"Suppl. 2","key":"BFnrneph2012289_CR147","first-page":"S13","volume":"78","author":"CL Bennett","year":"2011","unstructured":"Bennett, C. L. Pharmacovigilance and PML in the oncology setting. Clin. J. Med. 78 (Suppl. 2), S13\u2013S17 (2011).","journal-title":"Clin. J. Med."},{"key":"BFnrneph2012289_CR148","unstructured":"US Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Rituxan (rituximab)\u2013PML [online], (2012)."},{"key":"BFnrneph2012289_CR149","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/jmv.23339","volume":"84","author":"S Delbue","year":"2012","unstructured":"Delbue, S.  et al. Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab. J. Med. Virol. 84, 1464\u20131470 (2012).","journal-title":"J. Med. Virol."},{"key":"BFnrneph2012289_CR150","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3816\/CLM.2006.n.019","volume":"6","author":"Y Herishanu","year":"2006","unstructured":"Herishanu, Y.  et al. Fatal interstitial pneumonitis related to rituximab-containing regimen. Clin. Lymphoma Myeloma 6, 407\u2013409 (2006).","journal-title":"Clin. Lymphoma Myeloma"},{"key":"BFnrneph2012289_CR151","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","volume":"51","author":"AV Hadjinicolaou","year":"2012","unstructured":"Hadjinicolaou, A. V., Nisar, M. K., Parfrey, H., Chilvers, E. R. & Ostor, A. J. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 51, 653\u2013662 (2012).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrneph2012289_CR152","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/ppul.20864","volume":"44","author":"M Bitzan","year":"2009","unstructured":"Bitzan, M., Anselmo, M. & Carpineta, L. Rituximab (B-cell depleting antibody) associated lung injury (RALI): pediatric case and systematic review of the literature. Pediatr. Pulmonol. 44, 922\u2013934 (2009).","journal-title":"Pediatr. Pulmonol."},{"key":"BFnrneph2012289_CR153","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","volume":"24","author":"M Chaumais","year":"2009","unstructured":"Chaumais, M.  et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr. Nephrol. 24, 1753\u20131755 (2009).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012289_CR154","doi-asserted-by":"publisher","unstructured":"Ergin, A. B., Fong, N. & Daw, H. A. Rituximab-induced bronchiolitis obliterans organizing pneumonia. Case Reports Med. http:\/\/dx.doi.org\/10.1155\/2012\/680431.","DOI":"10.1155\/2012\/680431"},{"key":"BFnrneph2012289_CR155","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/ard.2007.083162","volume":"67","author":"D Albert","year":"2008","unstructured":"Albert, D.  et al. Variability in the biological response to anti-CD20 B-cell depletion in systemic lupus erythematosus. Ann. Rheum. Dis. 67, 1724\u20131731 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2012289_CR156","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/annonc\/mdf155","volume":"13","author":"T Igarashi","year":"2002","unstructured":"Igarashi, T.  et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann. Oncol. 13, 928\u2013943 (2002).","journal-title":"Ann. Oncol."},{"key":"BFnrneph2012289_CR157","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaci.2012.03.022","volume":"130","author":"L Lunardon","year":"2012","unstructured":"Lunardon, L. & Payne, A. S. Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus. J. Allergy Clin. Immunol. 130, 800\u2013803 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrneph2012289_CR158","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"RJ Looney","year":"2004","unstructured":"Looney, R. J.  et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580\u20132589 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012289_CR159","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis, T. A.  et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18, 3135\u20133143 (2000).","journal-title":"J. Clin. Oncol."},{"key":"BFnrneph2012289_CR160","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/11539590-000000000-00000","volume":"25","author":"T Robak","year":"2011","unstructured":"Robak, T. & Robak, E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 25, 13\u201325 (2011).","journal-title":"BioDrugs"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2012.289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2012.289","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2012.289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:56:47Z","timestamp":1744286207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2012.289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,22]]},"references-count":160,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["BFnrneph2012289"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2012.289","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,22]]},"assertion":[{"value":"22 January 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}